Pradimicin S, a new pradimicin analog. III. Application of the frit-FAB LC/MS technique to the elucidation of the pradimicin S biosynthetic pathway

J Antibiot (Tokyo). 1995 Feb;48(2):162-8. doi: 10.7164/antibiotics.48.162.

Abstract

The biosynthetic pathway of pradimicin S (PRM-S) was investigated by using sinefungin and bioconversion experiments with aglycones of pradimicin A (PRM-A) and Actinomadura spinosa AA0851, a PRM-S producer. Addition of sinefungin to the strain inhibited the formation of 11-O-demethyl-7-O-methylpradinone II (11dM-7M-PNII) as also determined to occur with its addition to the PRM-A producer. In feeding PRM-A aglycone and its analogs to the strain early in PRM-S biosynthesis, good identifications of bioconverted products were obtained by frit-FAB LC/MS as follows: 11-O-demethylpradinone II (11dM-PNII), 11dM-7M-PNII, 11-O-demethylpradinone I (11dM-PNI), 11-O-demethylpradimicinone I (11dM-PMNI) and pradimicinone I (PMNI) were converted to PRM-S. Pradimicin B (PRM-B) and pradimicin L (PRM-L) were converted to PRMs-L and -S and PRM-S, respectively. A biosynthetic pathway for PRM-S is proposed.

MeSH terms

  • Actinomycetales / metabolism
  • Anthracyclines*
  • Antibiotics, Antineoplastic / biosynthesis*
  • Antibiotics, Antineoplastic / chemistry
  • Antibiotics, Antineoplastic / metabolism
  • Biotransformation
  • Carbohydrate Sequence
  • Chromatography, High Pressure Liquid / methods*
  • Kinetics
  • Molecular Sequence Data
  • Spectrometry, Mass, Fast Atom Bombardment / methods*

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • pradimicin S